Key result
Aggressive CMV prophylaxis in heart transplant recipients reduced the relative risk of acute rejection graded >=3A compared with standard prophylaxis.
Why the study?
Does aggressive CMV prophylaxis reduce CMV infection, acute rejection, and cardiac allograft vascular disease in heart transplant recipients?
Cohort (n=66)
Does aggressive CMV prophylaxis reduce CMV infection, acute rejection, and cardiac allograft vascular disease in heart transplant recipients?
Prolonged aggressive CMV prophylaxis reduces subclinical CMV infection, acute rejection, and progression of cardiac allograft vascular disease in heart transplant recipients.
Answers are grounded in this paper and cite their sources.
Aggressive CMV prophylaxis was associated with lower rejection risk after heart transplant; hypothesis-generating and should not yet change practice.
BACKGROUND: Anticytomegalovirus (CMV) prophylaxis prevents the acute disease but its impact on subclinical infection and allograft outcome is unknown. We sought to determine whether CMV prophylaxis administered for three months after heart transplant would improve patient outcomes. METHODS: This prospective cohort study of 66 heart transplant recipients compared aggressive CMV prophylaxis (n = 21, CMV hyperimmune globulin [CMVIG] plus four weeks of intravenous ganciclovir followed by two months of valganciclovir); with standard prophylaxis (n = 45, intravenous ganciclovir for four weeks). Prophylaxis was based on pretransplant donor (D) and recipient (R) CMV serology: R-/D+ received aggressive prophylaxis; R+ received standard prophylaxis. Outcome measures were: CMV infection assessed by DNA-polymerase chain reaction on peripheral blood polymorphonuclear leukocytes, acute rejection, and cardiac allograft vascular disease (CAV) assessed by intravascular ultrasound. All patients completed one year of follow-up. RESULTS.: CMV infection was subclinical in all but four patients (two in each group). Aggressively treated patients had a lower incidence of CMV infection (73 +/- 10% vs. 94 +/- 4%; P = 0.038), and an independent reduced relative risk for acute rejection graded > or =3A (relative risk [95% CI] = 0.55 [0.26-0.96]; P = 0.03), as compared with the standard prophylaxis group. Aggressively prophylaxed patients also showed a slower progression of CAV, in terms of coronary artery lumen loss (lumen volume change=-21 +/- 13% vs. -10+/-14%; P = 0.05); and vessel shrinkage (vessel volume change = -15 +/- 11% vs. -3 +/- 18%; P = 0.03). CONCLUSIONS: Prolonged (val)ganciclovir plus CMVIG reduces viral levels, acute rejection, and allograft vascular disease, suggesting a role for chronic subclinical infection in the pathophysiology of the most common diseases affecting heart transplant recipients.
No takes yet. Share an insight, caveat, or question.
Potena et al. (2006) conducted a cohort in Heart transplant (n=66). Aggressive CMV prophylaxis vs. Standard prophylaxis (intravenous ganciclovir for 4 weeks) was evaluated on Acute rejection graded >=3A (RR 0.55, 95% CI 0.26-0.96, p=0.03). Aggressive CMV prophylaxis in heart transplant recipients reduced the relative risk of acute rejection graded >=3A compared with standard prophylaxis.
Synapse has enriched 10 related papers. Consider them for comparative context: